These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38030622)

  • 1. PD-1
    Cappuyns S; Philips G; Vandecaveye V; Boeckx B; Schepers R; Van Brussel T; Arijs I; Mechels A; Bassez A; Lodi F; Jaekers J; Topal H; Topal B; Bricard O; Qian J; Van Cutsem E; Verslype C; Lambrechts D; Dekervel J
    Nat Commun; 2023 Nov; 14(1):7825. PubMed ID: 38030622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Kuroyanagi K; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    Cancer Med; 2024 Jan; 13(1):e6876. PubMed ID: 38133557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
    Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
    Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
    Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
    Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating CD8 lymphocytes predict response to atezolizumab-bevacizumab in hepatocellular carcinoma.
    Gramantieri L; Suzzi F; Bassi C; D'Abundo L; Tovoli F; Bruccoleri M; Marseglia M; Alimenti E; Fornari F; Negrini M; Iavarone M; Piscaglia F; Giovannini C
    Eur J Immunol; 2024 Feb; 54(2):e2350637. PubMed ID: 37990855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
    Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
    Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.
    Yoo JS; Kim JH; Cho HS; Han JW; Jang JW; Choi JY; Yoon SK; Kim S; Oh JS; Chun HJ; Sung PS
    Abdom Radiol (NY); 2024 Sep; 49(9):3127-3135. PubMed ID: 38678485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8
    Li S; Li K; Wang K; Yu H; Wang X; Shi M; Liang Z; Yang Z; Hu Y; Li Y; Liu W; Li H; Cheng S; Ye L; Yang Y
    Nat Commun; 2023 Nov; 14(1):7709. PubMed ID: 38001101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
    Kim C; Yang H; Kim I; Kang B; Kim H; Kim H; Lee WS; Jung S; Lim HY; Cheon J; Chon HJ
    JAMA Oncol; 2022 Dec; 8(12):1825-1829. PubMed ID: 36264560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
    Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines.
    Geginat J; Lanzavecchia A; Sallusto F
    Blood; 2003 Jun; 101(11):4260-6. PubMed ID: 12576317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography.
    Uchikawa S; Kawaoka T; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Miki D; Imamura M; Aikata H
    J Med Ultrason (2001); 2023 Jan; 50(1):57-62. PubMed ID: 36169740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effector Memory-Expressing CD45RA (TEMRA) CD8
    Doan Ngoc TM; Tilly G; Danger R; Bonizec O; Masset C; Guérif P; Bruneau S; Glemain A; Harb J; Cadoux M; Vivet A; Mai HL; Garcia A; Laplaud D; Liblau R; Giral M; Blandin S; Feyeux M; Dubreuil L; Pecqueur C; Cyr M; Ni W; Brouard S; Degauque N; ;
    J Am Soc Nephrol; 2022 Dec; 33(12):2211-2231. PubMed ID: 36280286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
    Su CW; Teng W; Shen EY; Huang BS; Lin PT; Hou MM; Wu TH; Tsan DL; Hsieh CH; Wang CT; Chai PM; Lin CY; Lin SM; Lin CC
    Oncologist; 2024 Jul; 29(7):e922-e931. PubMed ID: 38530254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122
    Zhang Q; Su C; Luo Y; Zheng F; Liang CL; Chen Y; Liu H; Qiu F; Liu Y; Feng W; Dai Z
    Biomed Pharmacother; 2024 Oct; 179():117401. PubMed ID: 39243425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.